Terazosin HCl Dihydrate Clinical Trials

Size	Price	Qty
50mg	USD 147

Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 4 are evaluating Terazosin across various therapeutic areas. Beyond its established indication for benign prostatic hyperplasia, research extends to neurodegenerative disorders—including Parkinson's disease, amyotrophic lateral sclerosis, and dementia with Lewy bodies—as well as hyperhidrosis and carotid artery stenosis. Sponsored by academic institutions, research foundations, and pharmaceutical companies, these protocols encompass completed, actively recruiting, active non-recruiting, and pending studies.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07796308	NOT_YET_RECRUITING	Alzheimer s Disease	Qiang Zhang	2027-08-01	PHASE2
NCT07207057	RECRUITING	Parkinsons Disease (PD)	University College, London	2025-09-12	PHASE3
NCT04760860	NOT_YET_RECRUITING	Dementia With Lewy Bodies	Qiang Zhang	2027-10	PHASE1; PHASE2
NCT07288450	NOT_YET_RECRUITING	Parkinson's Disease	Nandakumar Narayanan	2026-09-01	PHASE1; PHASE2
NCT07464028	NOT_YET_RECRUITING	Parkinson's Disease (PD)	Nandakumar Narayanan	2026-07-01	PHASE2
NCT07224269	RECRUITING	Amyotrophic Lateral Sclerosis; Adenosine Triphosphate Activities	University of Iowa	2026-08-12	EARLY_PHASE1
NCT06966804	RECRUITING	Stent Related Symptoms	Penang Hospital, Malaysia	2025-06-01	PHASE3
NCT05855577	UNKNOWN	Parkinson Disease; Gait Analysis; Therapy, Directly Observed; Metabolic Disease	I.R.C.C.S. Fondazione Santa Lucia	2023-12	PHASE4
NCT05109364	ACTIVE_NOT_RECRUITING	Symptomatic Parkinson Disease; REM Sleep Behavior Disorder; Pre-motor Parkinson's Disease	Cedars-Sinai Medical Center	2022-09-23	PHASE2
NCT04386317	ACTIVE_NOT_RECRUITING	REM Sleep Behavior Disorder; Pre-motor Parkinson's Disease; Symptomatic Parkinson Disease	Cedars-Sinai Medical Center	2020-11-01	PHASE2
NCT04760860	Not yet recruiting	Dementia With Lewy Bodies	Qiang Zhang\|University of Iowa	2024-10	Phase 1\|Phase 2
NCT04551040	ACTIVE_NOT_RECRUITING	Healthy	University of Iowa	2021-03-26	PHASE1
NCT04551040	Active not recruiting	Healthy	University of Iowa\|Michael J. Fox Foundation for Parkinson''s Research	2021-03-26	Phase 1
NCT04386317	Recruiting	REM Sleep Behavior Disorder\|Pre-motor Parkinson''s Disease\|Symptomatic Parkinson Disease	Cedars-Sinai Medical Center	2020-11-01	Phase 2
NCT03905811	COMPLETED	Parkinson Disease	Jordan Schultz	2019-09-24	PHASE1; PHASE2
NCT02046395	COMPLETED	Type 2 Diabetes; Hypertension	Tulane University School of Medicine	2012-01	PHASE4
NCT03195673	UNKNOWN	Carotid Artery Stenosis	Capital Medical University	2018-03-02	PHASE2
NCT01508637	UNKNOWN	Cardiovascular Effects	University of Washington	2012-01
NCT00449683	COMPLETED	Hyperhidrosis	Thomas Jefferson University	2007-03	PHASE4
NCT01530243	COMPLETED	Disorder of Urinary Stent	Urmia University of Medical Sciences	2012-01	PHASE2; PHASE3
NCT01366664	COMPLETED	Ejaculation	Janssen Research & Development, LLC	2011-04	PHASE1
NCT00700583	COMPLETED	Nocturia	Seoul National University Hospital	2008-05
NCT00449683	Completed	Hyperhidrosis	Thomas Jefferson University\|National Alliance for Research on Schizophrenia and Depression	2007-03	Phase 4
NCT00693199	COMPLETED	Lower Urinary Tract Symptoms; Hypertension	Anhui Medical University	2006-07
NCT00237510	COMPLETED	Antidepressant Induced Excessive Sweating	Thomas Jefferson University	2005-05
NCT00237510	Completed	Antidepressant Induced Excessive Sweating	Thomas Jefferson University	2005-05	Not Applicable
NCT02244333	Completed	Prostatic Hyperplasia	Boehringer Ingelheim	2004-02	--
NCT00563485	TERMINATED	Prostatic Hyperplasia; Urinary Retention	Hospital Authority, Hong Kong	2005-10

(data from https://clinicaltrials.gov, updated on 2026-09-01)

Check the Terazosin HCl Dihydrate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Terazosin selectively binds to post-junctional alpha-1 adrenoceptors, competitively inhibiting catecholamine-induced activation and downstream intracellular calcium mobilization within target tissues. This signaling blockade promotes smooth muscle relaxation in vascular beds and the prostate stroma, thereby reducing peripheral vascular resistance and alleviating urinary outflow obstruction in clinical conditions such as benign prostatic hyperplasia and associated neurodegenerative disorders studied in clinical trials.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).